PDCD1 and neoplasm: Considering that preexisting T cells in the tumor are a requisite for response to anti-PD-1 therapy (166), the absence of reactive PD-L1 expression may implicate a poor response to PD-1 blockade therapy, because of the impairment of tumor-infiltrating T cells (164).